SEC Form 4 · accession 0001209191-15-033485
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jorge Plutzky M.D.
Director
Period of report
Apr 8, 2015
Accepted (ET)
Apr 10, 2015 · 8:46 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $25.99 | Apr 8, 2015 | A | 31,182 | A | — | Apr 8, 2025 | Common Stock | 31,182 | 31,182 | D |
Explanation of responses
- F1The 31,182 shares of common stock underlying this option will vest in equal one-third increments on April 8, 2016, April 8, 2017 and April 8, 2018.